| 翻訳と辞書 |
| Pacific Biosciences ： ウィキペディア英語版 |
Pacific Biosciences
Pacific Biosciences of California, Inc. is a biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation.〔(Businessweek (Dec 3, 2009) "WEF Announces 2010 Tech Pioneers" )〕〔(Nature Methods (Apr 15, 2010) "Single-molecule analysis: A ribosome in action" )〕 They describe their platform as single molecule real time sequencing (SMRT), based on the properties of zero-mode waveguides. Their first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011.〔(GenomeWeb (Dec 7, 2010) "PacBio Reveals Beta System Specs for RS; Says Commercial Release is on Track for First Half of 2011" )〕〔(GenomeWeb (May 3, 2011) "PacBio Ships First Two Commercial Systems; Order Backlog Grows to 44" )〕 A new version of the sequencer called the PacBio RS II was released in April 2013.〔(Next Gen Seq (Apr 11, 2013) "PacBio Launches PacBio RS II Sequencer" )〕〔(GenomeWeb (Apr 16, 2013) "New Products: PacBio's RS II; Cufflinks" )〕 On 25 September 2013 a partnership between Pacific Biosciences and Roche Diagnostics was announced for the development of in vitro diagnostic products using the technology, with Roche providing in the deal.〔(Pacific Biosciences to Partner With Roche on In Vitro Diagnostics Products )〕〔(The Motley Fool (Sep 25, 2013) "Pacific Biosciences Rockets on Roche Diagnostics Deal" )〕 In 2015, the company launched a new sequencing instrument called the Sequel System with approximately 7-fold greater capacity than the PacBio RS II.〔https://www.genomeweb.com/business-news/pacbio-launches-higher-throughput-lower-cost-single-molecule-sequencing-system〕〔http://www.bio-itworld.com/2015/9/30/pacbio-announces-sequel-sequencing-system.aspx〕
==History==
The company was founded based on research done at Cornell University, that combined semiconductor processing and photonics with biotechnology research.〔 It was initially founded under the name Nanofluidics, Inc. The company raised nearly in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year.〔(Wall Street Journal (Mar 9, 2010) "Sizing Up Promising Young Firms" )〕 Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Pacific Biosciences」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|